EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

2cureX AB (2CUREX) fair value: what the stock is really worth

As of Aug 31, 2026: fair value of 2cureX AB SEK 0.17, price SEK 0.42, upside -59.5%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · SE · ISIN SE0010468124

2A Thin data Sep 23, 2026

2cureX AB

2CUREX · ST

Weakest SetupStrongly overvalued and low quality.

!Fair value kr 0.1700 · Strongly overvalued (−60%)
!Quality 43/100
!Weak Growth (revenue 5y −54.2 %/yr)
!negative free cash flow
!Trails peers (3/8)
!Narrow moat 10/100
!Insider activity 35/100
!Evidence only low, so the estimate is less certain
Watch 2cureX AB for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

kr 19.32 kr 0.2532 Fair Value kr 0.1700 Jun 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range kr 0.2532 – kr 19.32 · fair‑value band kr 0.1105 – kr 0.2125 · the kr 0.4200 price screens above the kr 0.1700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow 2cureX in your weekly email

Every Wednesday you see whether 2cureX is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer.

Show more

2cureX AB (publ) operates as a medical technology company in Europe. ts proprietary IndiTreat test family creates various three-dimensional tumoroids derived from fresh samples of colorectal cancer (CRC) tissue that has been obtained from an individual patient's metastatic colorectal cancer. 2cureX AB (publ) was incorporated in 2006 and is based in Landskrona, Sweden.

Stock analysis

2cureX AB (2CUREX) currently trades at kr 0.4200, while our model-based Fair Value estimate is kr 0.1700, implying the stock looks roughly 147.0% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: kr 0.1105 (bear) to kr 0.2125 (bull), the price of kr 0.4200 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

2cureX AB reported revenue of 0 SEK in FY2024 versus 15.4M SEK in FY2020. Reported net income was −2.6M SEK in FY2025.

Key figures

Market cap 15.1M SEK (≈ $1.5M) · P/S ratio 7.62 · EPS (TTM) kr −0.4200 · Return on equity −175% · Return on assets (EBIT) −97.5% · Operating margin −1,924% · Revenue (TTM) 2.0M SEK · Revenue growth (YoY) −63.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).

What moves the price

The share trades about 85% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −60%, 2CUREX screens richer than that median.

Fair Value models

Bear kr 0.1105 Fair Value kr 0.1700 Bull kr 0.2125
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) kr 0.1000 kr 0.1400 kr 0.2000 51
All 1 models by family
Asset-Based
NCAV (Graham) kr 0.1000 kr 0.1400 kr 0.2000 51

Open the full fair value analysis →

Notify me when 2CUREX reaches fair value

Put 2CUREX on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 51 · Market factors (momentum, volatility) 4

Profitability 0
Margins and returns on capital today
Quality Growth 15
Are margins and returns improving?
Cashflow 92
Earnings quality: real cash, not paper profit
Fin. Strength 90
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 8
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+72.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−78.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−54.2%
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−28.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−109.9% (2018) → −23,460.0% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

2CUREX screens 147% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare 2cureX AB with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 651 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside −60% · Below median
Profitability
Return on assets −98% · Bottom 25%
Growth and dividend
Revenue growth −63% · Bottom 25%
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.30× · Cheapest 25%
P/S (TTM) 0.77× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $514.99 $566.49 +10%
Regeneron Pharmaceuticals, Inc REGN $803.90 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.24 A$197.16 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

2cureX AB · Fair Value
kr 0.1700 −147%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "2cureX AB Fair Value". https://www.fairvalue-calculator.com/stock/2CUREX

Frequently asked questions

Is 2cureX AB (2CUREX) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of kr 0.1700 versus the last price from Aug 31, 2026 of kr 0.4200, about −60% upside (overvalued).
What is the fair value of 2CUREX?
Our model-based fair value for 2cureX AB is kr 0.1700 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Aug 31, 2026): kr 0.4200.
What is the quality score of 2CUREX?
2cureX AB has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for 2cureX AB (2CUREX)?
Our model-based price target is the fair value of kr 0.1700 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario kr 0.1105, optimistic scenario kr 0.2125. It is a calculation from audited fundamentals, not an analyst target.
What is the 2cureX AB stock forecast for 2026?
Our models put fair value at kr 0.1700, about −60% upside versus the last price from Aug 31, 2026 of kr 0.4200 (overvalued). Cautious scenario kr 0.1105, optimistic scenario kr 0.2125. The calculation is refreshed regularly with new filings.
What is the revenue of 2cureX AB (2CUREX)?
2cureX AB reported trailing-twelve-month revenue of about 2.0M SEK (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of 2cureX AB (2CUREX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For 2cureX AB it is kr 0.1700 per share (as of Sep 23, 2026), against a price of kr 0.4200. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is 2cureX AB stock overvalued or undervalued in 2026?
As of Sep 23, 2026, 2CUREX trades above its calculated fair value: price kr 0.4200, fair value kr 0.1700, a gap of about −60% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2CUREX?
No. The price is what the market pays today (kr 0.4200); the fair value is what the company's own numbers justify (kr 0.1700). For 2cureX AB the two are kr 0.2500 per share apart. That gap is exactly why we show both numbers side by side.
How much is 2cureX AB worth?
The market values 2cureX AB at about 15.1M SEK (market capitalisation, as of Sep 23, 2026). Per share that is kr 0.4200; our models calculate a fair value of kr 0.1700 per share.
What do the bullish and bearish scenarios say about 2CUREX?
Our models span a range for 2cureX AB: cautious scenario kr 0.1105, base kr 0.1700, optimistic kr 0.2125 per share (as of Sep 23, 2026, price kr 0.4200). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of 2cureX AB (2CUREX)?
Balance-sheet figures for 2cureX AB (as of Sep 23, 2026): return on equity −174.8%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 2CUREX from its 52-week high?
2cureX AB trades at kr 0.4200, about 85% below its 52-week high of kr 2.74 and at the low of kr 0.4200 (as of Aug 31, 2026). Distance from the high says nothing about value: that is what the fair value of kr 0.1700 is for.
Which stocks are comparable to 2cureX AB?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is 2cureX AB stock attractive at the current price?
The data as of Sep 23, 2026: price kr 0.4200, calculated fair value kr 0.1700 (−60%), Quality Score 43/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2CUREX calculated?
We run 2cureX AB through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of kr 0.1700, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. 2cureX AB itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of 2cureX AB (2CUREX)?
The latest price we hold is from Aug 31, 2026 and stands at kr 0.4200. Our model-based fair value is kr 0.1700, about −60% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with 2cureX AB right now?
The price sits above even our optimistic bull case (kr 0.2125). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (kr 0.1105 to kr 0.2125) leaves room in how you read the outcome.

Key figures of 2cureX AB

How large is the market capitalisation of 2cureX AB (2CUREX)?
The market capitalisation of 2cureX AB is 15.1M SEK (≈ $1.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of 2cureX AB (2CUREX)?
The price-to-sales ratio of 2cureX AB is 7.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of 2cureX AB (2CUREX)?
Earnings per share at 2cureX AB are kr −0.4200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of 2cureX AB (2CUREX)?
The return on equity (ROE) of 2cureX AB is −175% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of 2cureX AB (2CUREX)?
On an EBIT basis the return on assets of 2cureX AB is −97.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of 2cureX AB (2CUREX)?
The operating margin of 2cureX AB is −1,924% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at 2cureX AB (2CUREX)?
Revenue at 2cureX AB is growing −63.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does 2cureX AB (2CUREX) generate?
The free cash flow of 2cureX AB is −4.6M SEK (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does 2cureX AB (2CUREX) hold?
2cureX AB holds more cash than debt, 5.1M SEK net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch 2cureX AB in the live analysis

One click puts 2cureX AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.